Stroke Prevention (@StrokePrevent) profile picture

The Foundation for Stroke Prevention. Steven Rudolph, MD, Director

New York
Joined February 2009
Photo by Stroke Prevention (@StrokePrevent)Photo by Stroke Prevention (@StrokePrevent)Photo by Stroke Prevention (@StrokePrevent)Photo by Stroke Prevention (@StrokePrevent)Photo by Stroke Prevention (@StrokePrevent)Photo by Stroke Prevention (@StrokePrevent)Photo by Stroke Prevention (@StrokePrevent)Photo by Stroke Prevention (@StrokePrevent)Photo by Stroke Prevention (@StrokePrevent)Photo by Stroke Prevention (@StrokePrevent)
Stroke Prevention retweeted
Prior to HORIZON we told our patients with elevated Lp(a) that lowering LDL-c to < 55mg/dl and and improving hs-CRP to < 2mg/L ( predominantly by weight loss) that CV risk will be potentially mitigated. HORIZON demonstrates that our recommendations were correct. Attached are figures in the NEJM Supplement that show this very clearly. In the Placebo arm with LDL-C < or > 70 the MACE rate is 10.2 vs 14.8% (45% higher) and CRP < or > 2 is 10.8 vs 16.6% (64% higher). In the subgroups with Lp(a) above or below the median the MACE were basically equivalent. Therefore in the setting of a modestly elevated LDL or CRP the CV risk is markedly elevated in high Lp(a) patients compared to those with low LDL/CRP. Therefore HORIZON teaches us that although lowering Lp(a) with an ASO does not modify the risk we can continue to confidently inform Lp(a) elevated patients of the need to aggressively lower LDL and inflammation (CRP). Much appreciation to Steve Nissen et al and Novartis for a landmark CVOT.
11
40
7
159
37,330
Stroke Prevention retweeted
🧵 In a post hoc analysis of the ATAMIS trial, the investigators found that among patients with acute #stroke, the benefit of clopidogrel plus aspirin versus aspirin alone was greater among patients with moderate stroke (NIHSS 6-10) than among those with mild stroke (NIHSS 4-5).
1
11
32
2,756
Stroke Prevention retweeted
Here are my initial thoughts on Lp(a)HORIZON. This is targeted to the people to whom it matters the most, my wonderful PATIENTS over the years in my Lp(a) Clinic. I have done my best to keep you healthy, and for the most part it worked. And I think this is reflected in the results of the Lp(a)HORIZON trial. This is also for those with elevated Lp(a) that been carrying significant anxiety and concern over their elevated levels. 1- Big picture: I do not see Lp(a)HORIZON as a failure, like many Monday morning quarterbacks out there who claim to have known the results all along after all. I see it as a MAJOR SUCCESS for our patients. 2- Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk: which is to: a) keep LDL-C below 65 or lower; b) keep blood pressure at 120 or lower; c) control all other risk factors as best as possible; d) take your medicines that have proven efficacy regularly. 3- I have called Lp(a)HORIZON testing the “Lp(a) Hypothesis”. Which means we did not know if lowering Lp(a) would benefit patients. If we knew Novartis would not have spent >1 billion dollars to do the trial and the FDA would have approved the drug simply on Lp(a) lowering. 4- Why did we not see a benefit in specifically lowering Lp(a) in Lp(a)HORIZON? I think we need to go back to “first principles” in how Lp(a) causes atherothrombosis. It is a minor contributor to atherosclerosis. It is a major contributor to inflammation, via OxPL. It is also anti-fibrinolytic- NOT pro-thrombotic. That means it contributes to vulnerable plaques but not to “plaque burden”. And it contributes to a blood clots enlarging and occluding blood vessels if clots are already made, but not in making blood clots per se. 5- So if one is intensively treated to remove the nidus for vulnerable plaques and clot formation, like the patients in HORIZON (and in the ongoing trials), then Lp(a) may become quiescent. 6- In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9i, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/triple/quadruple combo is highly effective. If I see no coronary calcium or evidence of atherosclerosis, I am not aggressive with therapy if otherwise not indicated for another reason. 7- That being said, 1 out of 8 people still had an event in Lp(a) HORIZON. So, we need to figure out why beyond classical lipids and blood pressure. I am already thinking 10 yrs ahead and will have new concepts for this issue in near future. 8- I do not think the Lp(a)HORIZON results apply to Aortic Stenosis, as this is not affected by LDL-C or for the most part aspirin, but is more @OxPL_apoB driven in people with high Lp(a). I think we owe a huge debt of gratitude for the Lp(a)HORIZON trial, to @novartis and to @ionispharma for leading the Lp(a) field. And to circle back to people with elevated Lp(a): Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients. We do need to do more work to figure out, among those with elevated Lp(a), who are highest risk, and target those in future studies, I will provide more scientific comments at a later time and will be publishing my thoughts in a journal in the future. With all that said, we still don't know the physiological function of Lp(a), if any, and why >99.99% have some circulating Lp(a) and why 1 in 5 have very high levels. Knowing this may give us the ultimate answer on Lp(a) and it role not only in CV disease but also in life and longevity. Along with my collaborators, we will have something on this also in near future. Thank you all for following Lp(a)'s journey in these pages. The story is actually in the middle not at the end...a few more chapters are in the works.
52
121
18
543
62,514
Stroke Prevention retweeted
The FDA is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. FDA fda.gov/safety/medical-produ…
12
70
9
160
33,879
FDA approves #asundexian based on OCEANIC-STROKE trial. A new generation of antithrombotic therapy for #stroke
3
123
Stroke Prevention retweeted
Today, we are informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of GLP-1 RA medications. NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. Symptoms of NAION include sudden, painless vision loss in one eye that patients may notice upon waking: visual defects such as blind spots, distortion of colors, blurriness, or tunnel vision. Patients should contact their health care professional right away if they have any of these symptoms. fda.gov/drugs/drug-safety-co…
36
201
51
403
90,466
Stroke Prevention retweeted
#MondayTip 📉After ischemic stroke or TIA, how low should systolic BP go? 🧠In OPTIMAL-STROKE, a target <120 vs <140 mm Hg reduced MACEs (10.9% vs 13.5%) over 3.9 years 💧Renal events were more frequent 🔍Monitor kidney function as you titrate 🔗nejm.org/doi/full/10.1056/NE…
🤖 Made with AI
1
29
1
68
4,116
Stroke Prevention retweeted
Original Article: Intensive Blood-Pressure Control in Patients with Previous Ischemic Stroke (OPTIMAL-STROKE trial) nej.md/3UasT1O #ScientificSessions26 | @AHAScience
2
27
1
114
17,953
Stroke Prevention retweeted
Presented at #ScientificSessions26: Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo. Full phase 3 Lp(a)HORIZON trial results: nej.md/4AcZL9n @AHAScience
15
119
31
338
53,666
Stroke Prevention retweeted
A new era in secondary stroke prevention is on the horizon! Factor XIa inhibitors represent a potential paradigm shift in antithrombotic therapy for secondary stroke prevention, decreasing AIS without increased bleeding. 🌊🧠 ahajournals.org/doi/epub/10.… #Stroke #OCEANICSTROKE
1
23
95
3,578
Stroke Prevention retweeted
REDUCE results presented at #ScientificSessions26 Spironolactone-based blood pressure management significantly reduced home SBP compared with standard care at 3 months, with the reduction sustained at 6 months.
12
37
2,044
Stroke Prevention retweeted
When a claim of noninferiority hides factual inferiority! Data do not support statin discontinuation is safe with respect to MACE.
Presented at #ScientificSessions26: In older adults with at least two chronic conditions and no known atherosclerotic cardiovascular disease, statin discontinuation was noninferior to continuation for a composite of myocardial infarction, stroke, or death at 2 years. Full STREAM trial results: nej.md/47U1X9N @AHAScience
10
30
1
141
13,274
Stroke Prevention retweeted
Presented at #ScientificSessions26: In patients with previous ischemic stroke or transient ischemic attack, a systolic blood-pressure target below 120 mm Hg was associated with fewer major cardiovascular events than a target below 140 mm Hg. Full OPTIMAL-STROKE trial results: nej.md/3UasT1O @AHAScience
12
156
17
473
46,580
Stroke Prevention retweeted
In a prospective observational cohort study, accumulation of high light-intensity physical activity was associated with early independent walking. @shimizu_natsu @kim_kgupt #stroke ahajrnls.org/3X7U7XG
18
1
39
4,332
Stroke Prevention retweeted
James C. Grotta, MD, reviews issues related to intravenous thrombolysis for stroke, including the choice of agent, dose, and timing and the relation to endovascular thrombectomy. Read the Review Article “Intravenous Thrombolysis for Acute Ischemic Stroke — New Directions”: nej.md/4iuL5Lr
3
162
1
588
36,606
Cover Story | Inflammation as a Treatable Target: The Rise of Cardio-Immunology - American College of Cardiology acc.org/Latest-in-Cardiology…
1
2
465
Stroke Prevention retweeted
#BloggingStroke: "Sleep and Stroke: Could Your Sleep Be Putting Your Brain at Risk?" by Elisabetta Soldini. #WorldStrokeDay ahajournals.org/do/10.1161/b…
5
5
1,227
Stroke Prevention retweeted
Stroke or ARIA? For Alzheimer’s disease patients on antiamyloid therapy, distinguishing between stroke and ARIA can have major treatment implications. This outlines a practical workflow emphasizing MRI evaluation, specialist consultation, and tailored decision-making based on symptom severity and treatment history. More here in @JAHA: ahajournals.org/doi/10.1161/… @SMGreenbergNeur @costantinoiade1 @SherryChou399 @MitchElkind @BJHicksMD @lauren_massimo @sudha_md @KristineYaffe @k_sauser
4
14
3
30
5,874
Stroke Prevention retweeted
🧵 Part 1 of this two-part topical review by Lin and Cramer that explores neural repair after #stroke⚙️: Intensive training can improve function even in the chronic phase, while biological therapies and neural stimulation offer emerging paths to recovery. ahajournals.org/doi/full/10.…
1
3
11
1,895